Tower Research Capital (TRC)’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-2,478
| Closed | -$1K | – | 6580 |
|
|
2023
Q1 | $1K | Buy |
+2,478
| New | +$1.97K | ﹤0.01% | 5725 |
|
|
2022
Q2 | – | Sell |
-1,092
| Closed | -$8K | – | 6832 |
|
|
2022
Q1 | $8K | Buy |
1,092
+284
| +35% | +$1.65K | ﹤0.01% | 4649 |
|
|
2021
Q4 | $5K | Buy |
808
+117
| +17% | +$1.2K | ﹤0.01% | 5240 |
|
|
2021
Q3 | $8K | Sell |
691
-1,388
| -67% | -$19.2K | ﹤0.01% | 4594 |
|
|
2021
Q2 | $39K | Buy |
2,079
+2,019
| +3,365% | +$37.6K | ﹤0.01% | 3249 |
|
|
2021
Q1 | $1K | Buy |
+60
| New | +$1.52K | ﹤0.01% | 5253 |
|
|
2017
Q4 | – | Sell |
-9
| Closed | -$4K | – | 4185 |
|
|
2017
Q3 | $4K | Sell |
9
-20
| -69% | -$10.4K | ﹤0.01% | 3428 |
|
|
2017
Q2 | $17K | Buy |
+29
| New | +$17K | ﹤0.01% | 1324 |
|
|
2016
Q2 | – | Sell |
-4
| Closed | -$2K | – | 5152 |
|
|
2016
Q1 | $2K | Buy |
4
+3
| +300% | +$1.12K | ﹤0.01% | 3489 |
|
|
2015
Q4 | $1K | Sell |
1
-1
| -50% | -$723 | ﹤0.01% | 4213 |
|
|
2015
Q3 | $3K | Buy |
+2
| New | +$3.06K | ﹤0.01% | 3198 |
|
|
2015
Q2 | – | Sell |
-2
| Closed | -$2K | – | 5205 |
|
|
2015
Q1 | $2K | Buy |
+2
| New | +$2.37K | ﹤0.01% | 3862 |
|
|
2014
Q4 | – | Sell |
-18
| Closed | -$24K | – | 4877 |
|
|
2014
Q3 | $24K | Buy |
18
+12
| +200% | +$17.2K | ﹤0.01% | 2168 |
|
|
2014
Q2 | $9K | Buy |
6
+3
| +100% | +$5.71K | ﹤0.01% | 2467 |
|
|
2014
Q1 | $6K | Sell |
3
-2
| -40% | -$5.12K | ﹤0.01% | 3148 |
|
|
2013
Q4 | $11K | Buy |
+5
| New | +$10.8K | ﹤0.01% | 2928 |
|
Other funds holding VYNT
Tower Research Capital (TRC)'s VYNT Position: Q2 2023 in Review
Tower Research Capital (TRC) sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q2 2023, closing a stake of 2,478 shares — an estimated $1K sold.
Tower Research Capital (TRC) first reported a position in VYNT in Q4 2013 and held it in 16 quarters. The position peaked at $39K in Q2 2021. 1 fund tracked by Wall St. Rank holds VYNT as of Q2 2023.
- Tower Research Capital (TRC) reported no remaining Vyant Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Tower Research Capital (TRC) sold 2,478 Vyant Bio, Inc. Common Stock shares in Q2 2023, an estimated $1K.
- Tower Research Capital (TRC) first reported a position in Vyant Bio, Inc. Common Stock in Q4 2013 and held it in 16 quarters.
- Tower Research Capital (TRC)'s Vyant Bio, Inc. Common Stock position peaked at $39K in Q2 2021.
- 1 fund tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q2 2023.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2023, filed 14 Aug 2023.